Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOVARB: 24-hour vs 72-hour Octreotide for Bleeding Esophageal Varices
NCT03624517Phase 4Terminated
- Sponsor
- Medical University of South Carolina
- Start
- Sep 2018
- Primary completion
- Dec 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of Octreotide long-acting injection in esophageal varices (2 arms), sponsored by Medical University of South Carolina. Primary endpoint: Esophageal Varices Rebleed at 72 hours. Started Sep 2018; status: terminated.
02
Drugs
Octreotide long-acting injection
03
Conditions
esophageal varices
Beyond the preview
Go deeper on NCT03624517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624517.